DealsMay 19, 2026, 05:12 PM
Genenta Science Terminates License Agreement with Ospedale San Raffaele
AI Summary
Genenta Science S.p.A. announced the termination of its amended and restated license agreement with Ospedale San Raffaele S.r.l. (OSR), effective May 18, 2026. This strategic decision, approved by the Board of Directors, will end the licenses and option rights related to certain technology and intellectual property. The company does not expect to incur any material termination fees or penalties, aside from accrued obligations, and plans to reallocate resources to other strategic initiatives while continuing to support the ongoing glioblastoma multiforme clinical trial.
Key Highlights
- Genenta Science's Board of Directors approved the termination of its license agreement with Ospedale San Raffaele (OSR) on May 18, 2026.
- The agreement covered certain technology and intellectual property rights licensed by OSR to Genenta Science.
- The termination will end licenses and option rights, subject to surviving provisions and accrued obligations.
- Genenta Science does not anticipate incurring any material termination fees or penalties.
- The decision was made following a review of strategic priorities and resource allocation.
- Resources will be reallocated towards ongoing business and strategic initiatives.
- The glioblastoma multiforme (GBM) clinical trial remains active with two patients under observation.
Price Impact
More from GNTA